Host inflammatory responses to Plasmodium falciparum GPI (pfGPI) anchors are believed to play an important role in the pathophysiology of severe malaria. However, relatively little is known about the signal transduction pathways involved in pfGPI-stimulated inflammatory response and its potential contribution to severe malaria syndromes. In this study, we investigated the role of MAPK activation in pfGPI-induced cytokine secretion and examined the role of selected MAPKs in a model of cerebral malaria in vivo. We demonstrate that ERK1/2, JNK, p38, c-Jun, and activating transcription factor-2 became phosphorylated in pfGPI-stimulated macrophages. A JNK inhibitor (1,9-pyrazoloanthrone) inhibited pfGPI-induced phosphorylation of JNK, c-Jun, and activating transcription factor-2 and significantly decreased pfGPI-induced TNF-alpha secretion. pfGPI-stimulated JNK and c-Jun phosphorylation was absent in Jnk2(-/-) macrophages but unchanged in Jnk1(-/-) and Jnk3(-/-) macrophages compared with wild-type macrophages. Jnk2(-/-) macrophages secreted significantly less TNF-alpha in response to pfGPI than macrophages from Jnk1(-/-), Jnk3(-/-), and wild-type counterparts. Furthermore, we demonstrate a role for JNK2 in mediating inflammatory responses and severe malaria in vivo. In contrast to wild-type or Jnk1(-/-) mice, Jnk2(-/-) mice had lower levels of TNF-alpha in vivo and exhibited significantly higher survival rates when challenged with Plasmodium berghei ANKA. These results provide direct evidence that pfGPI induces TNF-alpha secretion through activation of MAPK pathways, including JNK2. These results suggest that JNK2 is a potential target for therapeutic interventions in severe malaria.

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.177.9.6344DOI Listing

Publication Analysis

Top Keywords

severe malaria
16
plasmodium falciparum
8
cerebral malaria
8
inflammatory responses
8
malaria vivo
8
c-jun activating
8
activating transcription
8
transcription factor-2
8
jnk c-jun
8
tnf-alpha secretion
8

Similar Publications

Recent updates in the WHO guidelines for malaria case management.

Sudan J Paediatr

January 2024

Independent Consultant, Lawrenceville, Georgia, USA.

This is a brief review that highlights recent updates in malaria case management. Recent WHO revisions include a new artemisinin-based molecule (artesunate-pyronaridine), revising the recommendations for treating uncomplicated malaria during the first trimester of pregnancy and optimising primaquine dose to prevent relapses. The review also highlights innovative ideas to improve the implementation of guidelines for severe malaria and pre-referral treatment with rectal artesunate.

View Article and Find Full Text PDF

In 2023, Indonesia's Ministry of Health reported that nearly 75% of districts and cities in the country were free from malaria transmission, meaning 90% of the population lived in malaria-free zones. However, Papua Province, which accounts for only 1.5% of Indonesia's population, continues to contribute over 90% of the national malaria cases, with more than 16,000 reported cases in 2023.

View Article and Find Full Text PDF

Background: Malaria infection has caused a significant morbidity and mortality, notably in high-risk groups. Some evidence showed that ABO blood types might associate with malaria severity. This study aimed to determine the relationship between blood types and malaria severity in Papua, as Papua is a malaria-endemic area.

View Article and Find Full Text PDF

Guillain-Barré syndrome following falciparum malaria infection: a case report.

BMC Neurol

January 2025

Department of Radiology, School of Medicine, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Teferi, Ethiopia.

Background: Malaria is an infectious disease caused by Plasmodium parasites, transmitted to humans by infected female Anopheles mosquitoes. Five Plasmodium species infect humans: P. vivax, P.

View Article and Find Full Text PDF

Clarification of factors associated with post-artesunate delayed hemolysis (PADH): analysis of 327 patients with severe imported Plasmodium falciparum malaria in France.

Travel Med Infect Dis

January 2025

Centre National de Référence du Paludisme, Paris, France; Centre de Recherche en Epidémiologie et Santé des Populations (CESP), INSERM U1018, Paris, France; Université Paris-Saclay, Service des Maladies infectieuses et tropicales, APHP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Société Française de Médecine des Voyages.

Background: Post-Artesunate delayed hemolysis (PADH) occurs in approximately 15% of treated patients 2 to 3 weeks after artesunate administration. Identifying risk markers for PADH would help predict which patients are at higher risk.

Methods: In this prospective national cohort study conducted in a non-malaria endemic area from 2011 to 2016, a Cox proportional hazards model was used to assess the association between clinical and biological data available at Day 0 and the occurrence of PADH within 30 days of artesunate administration.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!